Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

Fig. 4

Estimated relationships between ScoreMDA and FACIT-F total score (a), SF-36v2 PCS (b), EQ-5D-3L VAS (c), and EQ-5D-3L UI (d). Data from OPAL Broaden (N = 422) and OPAL Beyond (N = 394); all treatment groups from each phase 3 study were pooled for analysis. SF-36v2 PCS: norm-based scores were used (a score of 50 representing the mean for the general population, with higher scores indicating less impairment); ScoreMDA: continuous MDA with values from 0 to 7 (0–4, no MDA; 5–7, MDA). EQ-5D-3L, EuroQoL-Five Dimensions-Three Level Health Questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MDA, minimal disease activity; PCS, Physical Component Summary; SF-36v2, Short Form-36 Health Survey Version 2, acute; UI, utility index, VAS, visual analog scale

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us